{
    "nctId": "NCT02239315",
    "briefTitle": "Study of Tumor RNA Disruption Assay\u2122 (RDA)",
    "officialTitle": "Study of Tumor RNA Disruption Assay\u2122 (RDA) and Its Association With a Response to Neoadjuvant Chemotherapy in Breast Cancer - A Prospective Mixed-Methods Study",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "The association between RDA score and pathological complete response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female,18 years or older;\n* Able to read and write in English:\n* With palpable cancer \\> 2cm (T2, T3) on clinical examination or clinical diagnosis of locally advanced breast cancer (LABC) (T3 or T4; or N2 or N3, according to TNM cancer staging including inflammatory breast cancer);\n* Must have histological proof of breast cancer (invasive ductal or infiltrating lobular);\n* Scheduled to receive neoadjuvant chemotherapy as part of their treatment plan;\n* Agree to have FNAB after the first, second and third cycle of chemotherapy, and if the chemotherapy regimen is changed, an additional FNAB after the first cycle of the new chemotherapy.\n\nExclusion Criteria:\n\n* Subjects who have had surgery, neoadjuvant chemotherapy or radiotherapy for the current breast cancer;\n* Subjects who are pregnant or breast feeding;\n* Subjects with Stage IV breast cancer;\n* Psychiatric or addictive disorders that may limit the ability to give informed consent or complete the trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}